SG11202001397VA - Methods of using dipivefrin - Google Patents
Methods of using dipivefrinInfo
- Publication number
- SG11202001397VA SG11202001397VA SG11202001397VA SG11202001397VA SG11202001397VA SG 11202001397V A SG11202001397V A SG 11202001397VA SG 11202001397V A SG11202001397V A SG 11202001397VA SG 11202001397V A SG11202001397V A SG 11202001397VA SG 11202001397V A SG11202001397V A SG 11202001397VA
- Authority
- SG
- Singapore
- Prior art keywords
- dipivefrin
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Mobile Radio Communication Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762555854P | 2017-09-08 | 2017-09-08 | |
PCT/US2018/050223 WO2019051387A1 (en) | 2017-09-08 | 2018-09-10 | METHODS OF USING DIPIVECHINE |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202001397VA true SG11202001397VA (en) | 2020-03-30 |
Family
ID=63686134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202001397VA SG11202001397VA (en) | 2017-09-08 | 2018-09-10 | Methods of using dipivefrin |
Country Status (14)
Country | Link |
---|---|
US (2) | US11213496B2 (ja) |
EP (1) | EP3678648B1 (ja) |
JP (2) | JP6837700B2 (ja) |
KR (1) | KR102182559B1 (ja) |
CN (1) | CN111565716B (ja) |
AU (1) | AU2018330329B2 (ja) |
BR (1) | BR112020004586A2 (ja) |
CA (1) | CA3075271C (ja) |
DK (1) | DK3678648T3 (ja) |
EA (1) | EA202090637A1 (ja) |
ES (1) | ES2954361T3 (ja) |
IL (1) | IL272851B (ja) |
SG (1) | SG11202001397VA (ja) |
WO (1) | WO2019051387A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202001397VA (en) | 2017-09-08 | 2020-03-30 | Insignis Therapeutics Inc | Methods of using dipivefrin |
EP3930685A1 (en) * | 2019-03-01 | 2022-01-05 | Insignis Therapeutics, Inc. | Dipivefrin orally disintegrating tablet formulations |
CN111803635B (zh) * | 2020-06-17 | 2023-03-14 | 中国医学科学院基础医学研究所 | 小分子抑制剂在治疗呼吸道病毒性肺炎上的应用 |
WO2023076477A2 (en) | 2021-10-27 | 2023-05-04 | Insignis Therapeutics, Inc. | Orally disintegrating tablet for epinephrine prodrug formulations |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3904671A (en) * | 1969-04-01 | 1975-09-09 | Sterling Drug Inc | Esters of 3-(hydroxy or hydroxymethyl)-4-hydroxyphenyl aminomethyl ketones |
FI55988C (fi) * | 1971-10-19 | 1979-11-12 | Klinge Co Chem Pharm Fab | Foerfarande foer framstaellning av terapeutiskt anvaendbara o-acylfenoletanolaminer |
US3839584A (en) | 1972-08-31 | 1974-10-01 | Interx Research Corp | Pharmaceutical compositions containing a novel ester of ((methylamino)methyl)benzyl alcohol and methods of using same |
US3809714A (en) * | 1972-08-31 | 1974-05-07 | Interx Research Corp | Novel ester of ((methylamino)methyl) benzyl alcohol |
US3868461A (en) | 1972-11-22 | 1975-02-25 | Interx Research Corp | Ester of 3,4-dihydroxy-alpha (isopropylamino) methyl benzyl alcohol, composition and anti-asthma use thereof |
US4035405A (en) | 1976-07-09 | 1977-07-12 | Interx Research Corporation | Novel synthesis for preparing the hydrochloride salt of selected catecholamine derivatives |
US4180586A (en) | 1977-01-10 | 1979-12-25 | Interx Research Corporation | 3,4-Dipivalyl-α-[methylamino)methyl]benzyl alcohol as an adjunct in the treatment of circulatory shock |
US4094983A (en) | 1977-01-17 | 1978-06-13 | Interx Research Corporation | Method for reducing intraocular pressure in warm-blooded animals |
US4145441A (en) | 1977-11-04 | 1979-03-20 | Interx Research Corporation | Sympathomimetic amines exhibiting anti-hemorrhoidal activity |
FR2561916B1 (fr) | 1984-03-30 | 1987-12-11 | Lafon Labor | Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau |
US5622716A (en) | 1987-02-20 | 1997-04-22 | Farmarc Nederland B.V. | Process for preparing a retard product containing diltiazem for a single daily administration |
PL170554B1 (pl) | 1991-12-17 | 1996-12-31 | Fuisz Technologies Ltd | Sposób wytwarzania kompozycji przeciwwrzodowej PL PL PL |
US5654003A (en) | 1992-03-05 | 1997-08-05 | Fuisz Technologies Ltd. | Process and apparatus for making tablets and tablets made therefrom |
US5622719A (en) | 1993-09-10 | 1997-04-22 | Fuisz Technologies Ltd. | Process and apparatus for making rapidly dissolving dosage units and product therefrom |
US5895664A (en) | 1993-09-10 | 1999-04-20 | Fuisz Technologies Ltd. | Process for forming quickly dispersing comestible unit and product therefrom |
US5567439A (en) | 1994-06-14 | 1996-10-22 | Fuisz Technologies Ltd. | Delivery of controlled-release systems(s) |
US5925682A (en) | 1995-11-20 | 1999-07-20 | Immunotech Inc. | Epinephrine as inhibitor of cancerous tumors |
US6596298B2 (en) | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
KR20040018394A (ko) * | 2001-07-04 | 2004-03-03 | 썬 파마슈티컬 인더스트리스 리미티드 | 위 정체 제어되는 약물 전달 계 |
JPWO2003041740A1 (ja) | 2001-11-16 | 2005-03-03 | 味の素株式会社 | 腫瘍壊死剤 |
JP2004231557A (ja) * | 2003-01-30 | 2004-08-19 | Katsuyoshi Hori | エピネフリン含有抗腫瘍剤 |
AU2004233744A1 (en) | 2003-05-02 | 2004-11-11 | Warner-Lambert Company Llc | Fast dissolving orally consumable films containing a modified starch for improved heat and moisture resistance |
JP2006193440A (ja) * | 2005-01-12 | 2006-07-27 | Medorekkusu:Kk | β2刺激剤含有製剤 |
US20070059361A1 (en) | 2005-09-09 | 2007-03-15 | University Of Manitoba | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
WO2011109340A1 (en) * | 2010-03-01 | 2011-09-09 | Nova Southeastern University | Epinephrine nanop articles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
US20070202163A1 (en) * | 2005-09-09 | 2007-08-30 | Mutasem Rawas-Qalaji | Fast-disintegrating epinephrine tablets for buccal or sublingual administration |
US20150164827A1 (en) * | 2005-09-09 | 2015-06-18 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
US9877921B2 (en) | 2005-09-09 | 2018-01-30 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
JP2009527504A (ja) | 2006-02-23 | 2009-07-30 | イオメディックス スリープ インターナショナル エスアールエル | 良質な睡眠の誘導および維持のための組成物および方法 |
TW200817049A (en) * | 2006-06-05 | 2008-04-16 | Verus Pharmaceuticals Inc | Epinephrine dosing regimens comprising buccal, lingual or sublingual and injectable dosage forms |
PL2818184T3 (pl) * | 2007-11-16 | 2019-06-28 | Aclaris Therapeutics, Inc. | Kompozycje i sposoby do leczenia plamicy |
DE102008007198A1 (de) * | 2008-02-01 | 2009-08-13 | Infectopharm Arzneimittel Und Consilium Gmbh | Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften |
CA2853084C (en) | 2011-10-21 | 2022-04-26 | Nova Southeastern University | Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine |
US9789071B2 (en) | 2012-06-27 | 2017-10-17 | G2B Pharma, Inc. | Intranasal formulation of epinephrine for the treatment of anaphylaxis |
WO2015034822A1 (en) | 2013-09-03 | 2015-03-12 | G2B Pharma Inc. | Intranasal formulation for the treatment of cardiopulmonary resuscitation (cpr), cardiac life support (cls), anaphylaxis and/or anaphylactoid reactions |
GB201419257D0 (en) * | 2014-10-29 | 2014-12-10 | Jagotec Ag | Pharmaceutical compositions |
TWI746449B (zh) | 2015-07-20 | 2021-11-21 | 美商Ai治療公司 | 使用阿吡莫德治療癌症之方法 |
US20180297966A1 (en) | 2015-10-17 | 2018-10-18 | Innovative Anesthetics, Llc | Compounds, compositions, and methods of making and using the same |
CN106109459A (zh) * | 2016-06-22 | 2016-11-16 | 丁俣汀 | 盐酸地匹福林的药物组合物及其在生物医药中的应用 |
CN110418639B (zh) | 2016-11-13 | 2023-06-02 | 艾奥诺医药有限公司 | 肾上腺素前药的舌下或口含给药制剂 |
SG11202001397VA (en) | 2017-09-08 | 2020-03-30 | Insignis Therapeutics Inc | Methods of using dipivefrin |
EP3930685A1 (en) | 2019-03-01 | 2022-01-05 | Insignis Therapeutics, Inc. | Dipivefrin orally disintegrating tablet formulations |
-
2018
- 2018-09-10 SG SG11202001397VA patent/SG11202001397VA/en unknown
- 2018-09-10 US US16/126,766 patent/US11213496B2/en active Active
- 2018-09-10 EP EP18779156.1A patent/EP3678648B1/en active Active
- 2018-09-10 DK DK18779156.1T patent/DK3678648T3/da active
- 2018-09-10 CA CA3075271A patent/CA3075271C/en active Active
- 2018-09-10 WO PCT/US2018/050223 patent/WO2019051387A1/en unknown
- 2018-09-10 AU AU2018330329A patent/AU2018330329B2/en active Active
- 2018-09-10 BR BR112020004586-1A patent/BR112020004586A2/pt unknown
- 2018-09-10 ES ES18779156T patent/ES2954361T3/es active Active
- 2018-09-10 KR KR1020207010039A patent/KR102182559B1/ko active IP Right Grant
- 2018-09-10 CN CN201880055604.2A patent/CN111565716B/zh active Active
- 2018-09-10 JP JP2020524222A patent/JP6837700B2/ja active Active
- 2018-09-10 EA EA202090637A patent/EA202090637A1/ru unknown
-
2020
- 2020-02-23 IL IL272851A patent/IL272851B/en unknown
-
2021
- 2021-01-27 JP JP2021010767A patent/JP2021063135A/ja active Pending
- 2021-11-30 US US17/538,749 patent/US20220193010A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US11213496B2 (en) | 2022-01-04 |
IL272851A (en) | 2020-04-30 |
CN111565716B (zh) | 2023-06-09 |
EP3678648A1 (en) | 2020-07-15 |
DK3678648T3 (da) | 2023-09-11 |
JP6837700B2 (ja) | 2021-03-03 |
ES2954361T3 (es) | 2023-11-21 |
BR112020004586A2 (pt) | 2020-09-08 |
AU2018330329A1 (en) | 2020-03-12 |
US20220193010A1 (en) | 2022-06-23 |
WO2019051387A1 (en) | 2019-03-14 |
AU2018330329B2 (en) | 2020-12-03 |
KR20200040898A (ko) | 2020-04-20 |
IL272851B (en) | 2021-12-01 |
CA3075271C (en) | 2021-10-12 |
EP3678648B1 (en) | 2023-07-26 |
JP2021063135A (ja) | 2021-04-22 |
KR102182559B1 (ko) | 2020-11-24 |
JP2020528928A (ja) | 2020-10-01 |
CA3075271A1 (en) | 2019-03-14 |
CN111565716A (zh) | 2020-08-21 |
EA202090637A1 (ru) | 2020-06-29 |
US20190076378A1 (en) | 2019-03-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL286316A (en) | New micro-dystrophins and related method of use | |
ZA202006746B (en) | Methods of treatment | |
HK1232140A1 (zh) | 微類器官以及製造和使用它們的方法 | |
HK1258062A1 (zh) | 給予惡拉戈利的方法 | |
AU364417S (en) | Back of the case | |
HUE057926T2 (hu) | Eljárás tiokarbonátok elõállítására | |
GB2600653B (en) | Novel methods | |
IL268731A (en) | New uses of anti-SIRPG antibodies | |
IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
IL273493A (en) | Modified CAR-T | |
IL272851B (en) | Methods for using dipifaprin | |
SI3254474T1 (sl) | Elektroakustični implantat | |
EP3894768C0 (en) | METHOD FOR CRYOHARDENING | |
ZA201706282B (en) | Solid forms of menaquinols | |
GB201703036D0 (en) | Methods | |
SG11202005850VA (en) | Methods of treatment of hypertrigl yceridemia | |
HUE057149T2 (hu) | Mikromolekula vegyület, eljárás szintézisére és alkalmazására | |
DK3615520T3 (en) | Methods | |
GB201721386D0 (en) | Chrondogy of time-wave | |
GB201810835D0 (en) | Methods of use | |
GB201719043D0 (en) | Methods and compounds | |
GB201721724D0 (en) | Gametogenesis | |
GB201715203D0 (en) | Novel methods | |
GB201715089D0 (en) | Novel methods | |
PT3471835T (pt) | Utilização de extratos de deschampsia antarctica para combater danos na barreira cutânea humana provocados por agressões ambientais |